Granulocyte counts in randomized patients treated with and without GM-CSF priming.

Geometric mean curves (with approximate 66% confidence limits) of individual patient granulocyte counts for patients treated with topotecan with (n = 23) and without (n = 26) GM-CSF priming. Individual patient curves were linearly interpolated on a log scale for days with missing values.